Figure 5.

Eligibility for PGx testing.

Flow diagram showing the likelihood of included patients being prescribed a ‘CYP2D6-PGx antipsychotic’ at any time (either currently or previously prescribed) and of the proportion that experienced two or more psychosis drug transitions. More specifically, the flow diagram shows that of those who experienced two or more transitions, 49 (20%) patients were prescribed two or more ‘CYP2D6-PGx antipsychotics’ and 56 (23%) patients met the suggested eligibility for having a PGx test, based on current guidelines (Van Westrhenen et al., 2021b).